The Private Equity and Healthcare teams advised Ampersand Capital Partners on the majority recapitalization of American Laboratory Products Company, Ltd. (ALPCO).
Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. ALPCO is a Salem, NH-based in vitro diagnostics company that offers specialty immunoassay products (IVD and RUO) primarily focused on the clinical gastroenterology and diabetes research segments.
Ampersand's investment will be used to support ALPCO's worldwide growth initiatives, including the expansion of the company's diagnostics test kit offering, broadening the company's geographic presence, and fueling internal R&D product development and production operations.
The Goodwin team was led by Jim Barrett and Eric Carlson.
Earlier this year, Goodwin advised Ampersand on the formation of Ampersand 2020 Limited Partnership (AMP-20), which closed with $690 million in limited partner commitments and continues the firm’s strategy of making growth-oriented investments within targeted sectors of the healthcare industry. Goodwin also recently counseled Ampersand on the sale of portfolio company Cellero to Charles River Laboratories International, and portfolio company Nexelis’ acquisition of AIT Bioscience.
For more details on the ALPCO acquisition, read the press release.
Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. ALPCO is a Salem, NH-based in vitro diagnostics company that offers specialty immunoassay products (IVD and RUO) primarily focused on the clinical gastroenterology and diabetes research segments.
Ampersand's investment will be used to support ALPCO's worldwide growth initiatives, including the expansion of the company's diagnostics test kit offering, broadening the company's geographic presence, and fueling internal R&D product development and production operations.
The Goodwin team was led by Jim Barrett and Eric Carlson.
Earlier this year, Goodwin advised Ampersand on the formation of Ampersand 2020 Limited Partnership (AMP-20), which closed with $690 million in limited partner commitments and continues the firm’s strategy of making growth-oriented investments within targeted sectors of the healthcare industry. Goodwin also recently counseled Ampersand on the sale of portfolio company Cellero to Charles River Laboratories International, and portfolio company Nexelis’ acquisition of AIT Bioscience.
For more details on the ALPCO acquisition, read the press release.